Skip to content

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status
Selina Luger, MD, weighs the promise and challenges of modern ALL care
Advancing care through collaborative science: A European perspective
SOHO 2026 Friday plenary features NIH scientist and aplastic anemia expert Dr. Neal S. Young
Dr. Maddocks previews Friday MCL session at SOHO 2026

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Lymphoma Roundtable

Lymphoma Roundtable Lymphoma Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

CELMoDs in the second-line setting in follicular lymphoma

by SOHO Insider Editors
January 31, 2026
0 Comments

Lymphoma Roundtable ASH 2025 Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

What are the therapeutic combinations in large cell lymphoma?

by SOHO Insider Editors
January 6, 2026
0 Comments

Lymphoma Roundtable ASH 2025 Lymphoma Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

What is the 2025 treatment landscape of follicular lymphoma?

by SOHO Insider Editors
January 2, 2026
0 Comments

Lymphoma Roundtable Lymphoma Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

How do you approach frontline patients in follicular lymphoma?

by SOHO Insider Editors
December 26, 2025
0 Comments

Lymphoma Roundtable Lymphoma Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

How do you approach a patient with POD24 in follicular lymphoma?

by SOHO Insider Editors
December 23, 2025
0 Comments

Lymphoma Roundtable Lymphoma Aggressive B-Cell Lymphomas Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

What are the obstacles in using CELLMoDs in DLBCL?

by SOHO Insider Editors
December 22, 2025
0 Comments

Lymphoma Roundtable Lymphoma Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

What are the areas of unmet needs in large cell lymphoma?

by Leah Sherwood
December 19, 2025
0 Comments

Lymphoma Roundtable Lymphoma Aggressive B-Cell Lymphomas Indolent B-Cell Lymphomas News Video Interviews

What is the 2025 treatment landscape in DLBCL?

by SOHO Insider Editors
December 18, 2025
0 Comments

Lymphoma Roundtable Cellular Therapy Lymphoma Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

What are future therapeutic combinations in follicular lymphoma?

by SOHO Insider Editors
February 5, 2025
0 Comments

Top Categories

Cellular Therapy

82

Leukemia

133

Lymphoma

141

Multiple Myeloma

120

Myelodysplastic Syndromes

49

Myeloproliferative Neoplasms

36

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Lymphoma Roundtable

CELMoDs in the second-line setting in follicular lymphoma

What are the therapeutic combinations in large cell lymphoma?

What is the 2025 treatment landscape of follicular lymphoma?

How do you approach frontline patients in follicular lymphoma?

How do you approach a patient with POD24 in follicular lymphoma?

What are the obstacles in using CELLMoDs in DLBCL?

What are the areas of unmet needs in large cell lymphoma?

What is the 2025 treatment landscape in DLBCL?

What are future therapeutic combinations in follicular lymphoma?

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status

Selina Luger, MD, weighs the promise and challenges of modern ALL care

Advancing care through collaborative science: A European perspective

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Lymphoma Roundtable

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms